Pain Medication for GU/ Kidney Disorder: 41.7% of denials overturned
In 12 California IMR decisions from 2018 to 2024, reviewers overturned 5 (41.7%). In the last five years: 37.5% of 8. 11 were medical-necessity disputes, 1 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 66.7% |
| 2023 | 1 | 0.0% |
| 2024 | 4 | 25.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 57.1% | 41.7% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 3 | 33.3% | 41.7% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for baclofen vaginal suppositories compounded medication. According to medical guidelines, “Experts agreed second-line therapies, such as tender point injection (TPI) and vaginal suppositories, can be added to pelvic floor physical therapy (PFPT) in patients whose progress has plateaued without sufficient improvement or who are not …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for lidocaine 5% 50 gm (60 day supply with one refill). In a randomized controlled clinical trial, researchers evaluated pain control during vulvar biopsy after treatment with either application of 5% lidocaine-prilocaine cream or injection of 1% lidocaine. The authors found that, “Patients randomized to lidocaine-prilocaine had a …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Belbuca Film or Hysingla Extended-Release Tablets.At issue in this case is whether the requested Belbuca Film is medically necessary for the treatment of the patient’s medical condition. If not, are Hysingla extended-release tablets medically necessary to treat the patient’s medical condition? The 2016 Centers for Disease Control …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Norco. The current Centers for Disease Control and Prevention (CDC) guidelines for opioid therapy state that, “If benefits outweigh risks of continued opioid therapy, clinicians should work closely with patients to optimize non-opioid therapies while continuing opioid therapy. If benefits do not outweigh risks of continued opioid …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Pain Medication denials for GU/ Kidney Disorder overturned?
In 12 California IMR decisions from 2018 to 2024, reviewers overturned 5 (41.7%). In the last five years: 37.5% of 8. 11 were medical-necessity disputes, 1 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.